Bioisosteric Replacement of Carboxylic Acids in PPAR Agonists: A Mini Review

Curr Top Med Chem. 2026 Jul 26. doi: 10.2174/0115680266466273260722130035. Online ahead of print.ABSTRACTPeroxisome proliferator-activated receptors (PPARs) are nuclear receptors that regulate metabolic homeostasis and represent important therapeutic targets for conditions such as type 2 diabetes, d

A Adriana Coricello

Methylmalonate Overload Despite Glycemic Control Drives Diabetic Heart Damage

Circ Res. 2026 Jul 29. doi: 10.1161/CIRCRESAHA.125.327192. Online ahead of print.ABSTRACTBACKGROUND: Despite optimal glycemic control, the heart failure burden remains substantial in diabetic patients. Metabolic remodeling is involved in this process, yet our current understanding is still in its in

S Shanjie Wang

When Hypertrophy Hides a Rarer Diagnosis: A Case of Danon Disease

S D Med. 2026 Feb;79(2):76-78.ABSTRACTDanon disease (DD) is a rare X-linked dominant lysosomal storage disorder caused by mutations in the LAMP2 gene. It is typically characterized by a triad of intellectual disability, skeletal myopathy, and cardiomyopathy. Due to the X-linked inheritance pattern,

S Sanjana Manimaran

Effect of empagliflozin on copeptin levels in patients with recent acute coronary syndrome and newly detected dysglycaemia: a post-hoc analysis of the SOCOGAMI randomized controlled trial

Cardiovasc Diabetol. 2026 Jul 28;25(1):212. doi: 10.1186/s12933-026-03312-y.ABSTRACTBACKGROUND: Copeptin, a surrogate marker for vasopressin secretion, is associated with cardiovascular disease, insulin resistance and dysglycaemia. The cardioprotective effects of sodium-glucose cotransporter 2 inhib

E Elena Fortin